 
 
 
 
 
 
 
  
 
 
 
NIDA CTN Protocol 0076- ot 
 
Clinical Decision Support for Opi[INVESTIGATOR_360243]: 
Pi[INVESTIGATOR_360244]  
(COMPUTE)  
 
 
 
 
Lead Investigators: Gavin Bart, MD, PhD; Rebecca Rossom, MD, MS  
  
  
May 8, 2018  
Version 1.2 
  

 NIDA CTN Protocol  -0076 -ot Protocol Version 1 .2 
 COMPUTE  May 8, 201 8 
 
 2  
 COMPUTE Team Members  
 
 Gavin Bart, MD, PhD (Co -LI) 
 Rebecca Rossom, MD, MS (Co -LI) 
 Lauren Crain, PhD (Co -I) 
 Thomas Elliott, MD (Co -I) 
 Patrick O’Connor, MD, MS, MA (Co -I) 
 Anne Pylkas, MD (Co-I) 
 JoAnn Sperl -Hillen, MD (Co -I) 
 Laurel Nightingale (PM)  
 Debbie McCauley  (Epic Programmer) 
 Rashmi Sharma (Epic Programmer)  
 Deepa Appana (Web Programmer)  
 Laurel Nightingale (Project Manager ) 
 Kristen Huntley, PhD (NIDA CCTN Protocol Coordinator)  
 David Li u, MD (NIDA CCTN Protocol Coordinator)  
 Robert Lindblad, MD  (NIDA CTN Clinical Coordinating  Center , Emmes, Chief 
Medical Monitor ) 
 Robert Gore -Langton, PhD  (Emmes, Senior  Investigator ) 
 NIDA CTN Protocol  -[ADDRESS_449103] OF ABBREVIATION S .............................................................................................................. 7  
2.0 STUDY SYNOPSIS  ........................................................................................................................... 7  
2.1 Study Objectives  ................................................................................................................. 7  
2.2 Study Design and Outcomes  .............................................................................................. 7  
2.3 Sample Size and Study Population  ..................................................................................... 8  
2.4 Treatment/Assessment/Intervention and Duration  ............................................................. 8  
2.5 Safety Reporting  ................................................................................................................. 8  
2.6 Analyses  .............................................................................................................................. 8  
3.0 STUDY SCHEMA  ............................................................................................................................. 9  
4.0 INTRODUCTION  ............................................................................................................................. 10 
4.1 Background and Significance to the Field ......................................................................... 10 
5.0 OBJECTIVES .................................................................................................................................. 11 
5.1 Primary Objectives  ............................................................................................................ 11 
5.2 Secondary Objective(s)  ..................................................................................................... 12 
6.0 STUDY DESIGN  ............................................................................................................................. 12 
6.1 Overview of Study Design ................................................................................................. 12 
6.2 Duration of Study and Visit Schedule  ............................................................................... 13 
7.0 STUDY POPULATION  ................................................................................................................... 13 
7.1 Participant Inclusion Criteria ............................................................................................. 13 
7.2 Participant Exclusion Criteria ................................ ............................................................  13 
7.3 Participant Recruitment  ..................................................................................................... 13 
8.0 SITE SELECTION  ........................................................................................................................... 14 
8.1 Number of Sites  ................................................................................................................ 14 
8.2 Site Characteristics  ........................................................................................................... 15 
8.3 Rationale for Site Selection  ............................................................................................... 15 
9.0 OUTCOME MEASURES  ................................................................................................................ 15 
9.1 Pri
mary Outcome Measure  ............................................................................................... 15 
9.2 Other Outcome Measures  ................................................................................................. 16 
10.0 STUDY PROCEDURES  .................................................................................................................. 16 
10.1 Phase 1: Translating the White Paper to an Epic -compatible CDS and Building and 
Testing the CDS (15 months)  ........................................................................................... [ADDRESS_449104] Initiation  ................................................................................................................. 16 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 4  
 10.1.2  Design and Planning  ......................................................................................................... 17 
10.1.3  Development  ..................................................................................................................... 18 
10.1.4  Testing .............................................................................................................................. 19 
10.2 Phase 2: Deploying and Testing the CDS in Primary Care (6 months)  ............................ 20 
10.3 Phase 3: Analysis and Reporting (3 months)  ................................................................... [ADDRESS_449105] Release Forms............................................... 20 
10.6 Baseline Visit  ..................................................................................................................... 21 
10.7 Randomization  .................................................................................................................. 21 
10.8 Treatment/Intervention  ...................................................................................................... 21 
10.9 Collection of Biospecimens  ............................................................................................... 21 
10.10  Premature Withdrawal of Participants ............................................................................... 21 
10.11  Study Halting Rules ........................................................................................................... 21 
10.12  Follow -Up .......................................................................................................................... 21 
10.13  Blinding  ............................................................................................................................. 21 
10.14  Participant Reimbursement  ............................................................................................... 21 
10.15  Retention Plan  ................................................................................................................... 21 
11.0 STUDY ASSESSMENTS  ................................................................................................................ 22 
11.1 Study Assessments ........................................................................................................... 22 
11.1.1  PCP Surveys  ..................................................................................................................... 22 
11.2 PC
P Use Reports  .............................................................................................................. 30 
11.3 General Measures ............................................................................................................. 30 
11.3.1  Inclusion/Exclusion ............................................................................................................ 30 
11.4 Locator Form  ..................................................................................................................... 31 
11.5 Demographics Form .......................................................................................................... 31 
11.6 PhenX Tier 1 ..................................................................................................................... 31 
11.7 End of Medication/End of Treatment Form  ....................................................................... [ADDRESS_449106]
udy Completion Form  .................................................................................................... 31 
11.9 Measures of Primary and Secondary Outcomes  .............................................................. 31 
11.10  Clinical and Safety Assessments  ...................................................................................... 32 
11.10.1  Adverse Events (AEs) and Serious Adverse Events (SAEs)  ............................................ [ADDRESS_449107]  ............................................................................................................... 33 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 5  
 12.0 TRAINING REQUIREMENT S ......................................................................................................... 33 
12.1 Overall  ............................................................................................................................... 33  
13.0 STATISTICAL DESIGN A ND ANALYSES  .................................................................................... 34 
13.1 General Design  ................................................................................................................. 34 
13.1.1  Study Hypothesis  .............................................................................................................. 34 
13.2 Primary and Secondary Outcomes (Endpoints)  ............................................................... [ADDRESS_449108] (HIPAA)  ................................................ 38 
17.8 Investigator Assurances  .................................................................................................... 38 
17.9 Financial Disclosure  .......................................................................................................... 39 
17.10  DEA Registration (Component for medication studies using controlled substances studies 
– use if applicable)  ............................................................................................................ 39 
17.11  IND Requirements (Component for IND studies – use if applicable)  ............................... [ADDRESS_449109] (DSMB)  ...................................................................... 41 
17.20.2  Adverse Events (AEs)  ....................................................................................................... 41 
18.0 DATA MANAGEMENT  ................................................................................................................... 42 
18.1 Study Timeline  .................................................................................................................. 42 
19.0 PUBLICATIONS AND OTHER RIGHTS  ........................................................................................ 43 
20.0 SIGNATURES  ................................................................................................................................. 44 
21.0 REFERENCES  ................................................................................................................................ 45 
22.0 APPENDIX A: ADVERSE EVENT REPORTING AND PROCEDURES  ........................................ 49 
23.0 APPENDIX B: DATA AND  SAFETY MONITORING PL AN .......................................................... [ADDRESS_449110]  
HPMG  HealthPartners Medical Group  
MAT  Medication -assisted therapy  
MD Medical doctor  
NIDA  National Institute on Drug Abuse  
NIH National Institutes of Health  
NP Nurse practitioner  
OUD  Opi[INVESTIGATOR_360245]  
2.0 STUDY SYNOPSIS  
2.1 Study  Objectives 
The primary objective of this pi[INVESTIGATOR_360246] (OUD) clinical 
decision support (CDS) tool for use in an electronic medical record (EMR) and obtain high primary 
care physician (PCP) usability and acceptability . The OUD -CDS is based on the NIDA -Blending 
Initiative white paper , “Clinical Decision Support for Opi[INVESTIGATOR_71081]: Working Group 
Report,” which itself is based on national evidence- based guidelines (American Society of 
Addiction Medicine (ASAM 2015), V A (VA 2015).  As such, this pi[INVESTIGATOR_360247].  The secondary objectives of this pi[INVESTIGATOR_360248]-finding, medication- assisted 
therapy  (MAT) and referral patterns pre- and post -CDS deployment for PCPs with and without 
CDS access.  
2.[ADDRESS_449111] the usability and acceptability of a CDS tool for OUD in primary care 
clinics.  Details of each phase are found in Section 10.0.  Phase 1 of the study involves translating 
the Blending Initiative White Paper into algorithms that are compatible with Epic and HPMG and 
PNMG workflows and then building and extensively testing the CDS.  Phase 1 lasts 15 months.  
Phase 2 of the study involves deploying and testing the usability of the CDS in primary care.  We 
will recruit 16 non-waivered PCPs from multiple clinics to receive access to the OUD -CDS  (8 MDs 
and 8 nurse practitioners (NPs) or physician assistants (PAs)) , as we ll as 16 non- waivered PCPs 
from multiple clinics who will not receive access to the OUD -CDS  (8 MDs and 8 NPs/PAs) . 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 8  
 Additionally, all 11 waivered PCPs (10 MDs, 1 NP) will be invited to participate and will receive 
access to the OUD -CDS.  All PCPs will complete baseline and 6- month surveys; PCPs with 
access to the OUD -CDS will also be asked and incentivized to submit feedback about the CDS 
via the feedback tab in the CDS.  A recruitment diagram can be found in Section 7.3.  Phase 2 
lasts 6 mo nths.  Phase 3 involves analysis and reporting of data and lasts 3 months.  
The study outcomes are delineated in the specific aims  in Sections 5.0 and 9.0 .  
2.3 Sample Size and Study Population  
This pi[INVESTIGATOR_360249] 16 non-waivered volunteer PCPs from multiple HPMG and PNMG 
primary care clinics in the HealthPartners integrated healthcare organization who will receive 
access to the OUD -CDS . This pi[INVESTIGATOR_360250] 16 non-waivered volunteer PCPs who 
will not receive access t o the OUD -CDS but, similar to intervention PCPs, will complete baseline 
and 6- month surveys.  Additionally, all 11 PCPs waivered to prescribe buprenorphine will be 
invited to participate in this pi[INVESTIGATOR_2268].   
2.4 Treatment/Assessment/Intervention  and Duration  
The intervention involves access to the OUD -CDS for approximately half of recruited PCPs. 
Survey -based assessment of confidence in OUD screening, assessment, treatment and referral 
will be compared before and after the 6- month pi[INVESTIGATOR_360251].  
 Metrics of OUD- CDS use will be monitored for each PCP with CDS access throughout the 6 -
month intervention period. Specifically, we will monitor rates of OUD -CDS use for eligible 
encounters (i.e., PCP with CDS access who has an encounter with a patient with OUD or with a 
patient identified by [CONTACT_46251]- CDS to be at high risk of OUD).  
2.[ADDRESS_449112] of  care in OUD treatment. PCPs are 
trained that, as with other clinical decision tools, the OUD -CDS is meant to supplement but not 
supersede clinical judgment. PCPs can choose to follow or not follow the guidance of the CDS at any given time for any given patient, and PCPs are trained to let the research team know via the Feedback tab in the CDS when their clinical judgment is inconsistent with the CDS. This feedback will be monitored by [CONTACT_360296].   
 
An independent CTN DSMB will monitor this study.  The DSMB will communicate regarding what 
type of reports will be needed, as well as frequency.  The CTN DSMB is responsible for conducting periodic reviews of accumulating safety and efficacy data. It will determine whether there is support for continuation of the trial, or evidence that study procedures should be changed, or if the trial should be halted, for reasons relating to the safety of the study participants, the efficacy 
of the treatment under study, or  inadequate trial performance (e.g., poor recruitment).  
2.[ADDRESS_449113] -
surveys of provider confidence in OUD screening, assessment, treatment and referral, as well as 
satisfaction with the OUD -CDS, will be described.  
3.0 STUDY SCHEMA   
Phase 1:
18 Months
Phase 2: 
6 Months
Phase 3:
6 Months
Translating the White Paper to an Epic compatible 
CDS and Building and Testing the CDS
Recruit PCPs at HP and PN
16 MDs , 16 NPs/PAs
All 11 waivered PCPs
11 PCPs with buprenorphine 
waiver : all will be assigned to 
arm with CDS access
32 PCPs without 
buprenorphine waiver : 
randomly assigned to arms 
with or without  CDS acces
16 non-waivered PCPs 
(8 MDs , 8 PAs/NPs)
Up to 11 waivered PCPs (10 
MDs , 1 NP)
16 non-waivered PCPs 
(8 MDs , 8 PAs/NPs)
All PCPs complete baseline survey
6-month pi[INVESTIGATOR_360252]  -[ADDRESS_449114] of an epi[INVESTIGATOR_360253] (Centers for Disease Control and Prevention 
2012) . Between [ADDRESS_449115] -month heroin use increased 75% while past -month non -
medical prescription opi[INVESTIGATOR_360254] (Substance Abuse and Mental Health 
Services Administration 2008; Substance Abuse and Mental Health Services Administration  
2014) . In 2015 there were approximately 2.5 million Americans with moderate -to-severe OUD 
(Grant et al. 2016; Substance Abuse and Mental Health Services Administration 2014) . 
Approximately 20% of these individuals entered into addiction treatment programs but, of these, only about 25% received MAT (Substance Abuse and Mental Health Services Administration 
2012) . Overall, less than 10% of these 2.5 million Americans received treatment in a doctor’s 
office  (Substance Abuse and Mental Health Services Administration 2014) .  
Because primary care is the most common point of healthcare contact [CONTACT_360297], identification and treatment of OUD in primary care may help reduce this significant treatment 
gap. While methadone is highly regulated, of limited geographic availability, and allowed only in 
licensed treatment programs, buprenorphine  is a cost effective treatment for OUD that can be 
deployed in specialty and primary care settings (Alford et al. 2011; Liebschutz et al. 2014; Moore et al. 2007; Schackman et al. 2012; Soeffing et al. 2009; Weiss et al. 2011 ) and monthly injections 
of extended- release naltrexone (XR -NTX) are showing promise for OUD in some general medical 
settings (Coviello et al. 2012) . Further, treating OUD in primary care may facilitate the diagnosis 
and treatment of unrecognized chronic medical conditions (Rowe et al. 2012) . 
Since its introduction in 2003, more than 35,[ADDRESS_449116] been licensed to prescribe buprenorphine for the treatment of OUD. Under current law, 23,982 of these can prescribe for up 
to 30 patients, 9,285 for up to 100 patients, and 2,525 for up to 275 patients 
(http://www.samhsa.gov/programs -campaigns/medication-assisted- treatment/physician-
program -data, accessed November 28, 2016). Fewer than 30% of trained physicians go on to 
prescribe buprenorphine and less than 60% of the overall buprenorphine treatment capacity i s 
filled (Arfken et al. 2010; Hutchinson et al. 2014; Kunins et al. 2012) . It is too soon to know if the 
recent addition of advance practice clinicians to those eligible to prescribe will impact access or capacity. Whatever the case, at least for physicians, there is an additional barrier beyond certification and training that is preventing the uptake of buprenorphine prescription. Compared to those who do prescribe buprenorphine, those who do not are more likely to endorse lack of 
institutional support as being a barrier. Other barriers identified by [CONTACT_360298]-
prescribers include lack of staff training, lack of confidence, poor access to clinical guidelines, and time constraints (Barry et al. 2009; Hutchinson et al. 2014; Netherland et al. 2009; Walley et al. 
2008) . Similar barriers have  been identified as limiting use of XR -NTX (Alanis -Hirsch et al. 2016) . 
The various iterations of the Physician Clinical Support System (PCSS) have attempted to provide 
free education and mentoring support to assist providers in using MAT for OUD (Egan et al. 2010) . 
This assistance is available as web- based documents, webinars, telementoring, and even as site 
visits arranged between mentors and providers. Unfortunately, these valuable services are rarely 
deployed or utilized during actual patient encounters.  
 NIDA CTN Protocol  -[ADDRESS_449117] become increasingly sophisticated and successful 
(Ammenwerth et al. 2012; Druss & Dimitropoulos 2013; Roshanov et al. 2012). Our team has 
developed CDS systems that have been shown to improve glucose and blood pressure control in adults with diabetes, increase recognition of adolescents with previously unrecognized hypertension, have 60- 80% use rates at targeted primary care clinical encounters, and have 95% 
primary care provider satisfaction ratings (Desai et al. 2013; Gilmer et al. 2012; Kharbanda et al. 
2015; O'Connor et al. 2009; O'Connor et al. 2011; Sperl -Hillen et al. 2 010). These CDS systems, 
which focus on cardiovascular risk factor identification and management, have been used daily 
for the past 3 -4 years in the care of 1.5 million patients in 3 large healthcare delivery systems and 
will soon be deployed to an additional large healthcare system. NIH funding has been secured to 
expand this CDS system to include identification and management of additional chronic 
conditions. It is now technically feasible to extend this technology to support the systematic,  
timely, and safe management of those with OUD in primary care and other settings.  
Currently, providers lack real -time CDS tools that can efficiently facilitate personalized 
identification, assessment, and treatment of patients with OUD prior to or during a clinical 
encounter. The NIDA CTN Blending Initiative has developed an expert panel framework for an 
OUD- CDS. The framework has been previewed by [CONTACT_360299] 2015 International Network on 
Brief Interventions for Alcohol and Other Drugs (INEBRIA) conference. It is felt that any further refinements needed are best identified through pi[INVESTIGATOR_360255], including workflow issues, can be addressed.  
5.0 OBJECTIVES  
5.1 Primary Objective s  
1) To program an OUD -CDS tool based on a NIDA -Blending Initiative white paper “Clinical 
Decision Support for Opi[INVESTIGATOR_71081]: Working Group Report” and national guidelines (VA (VA 2015), ASAM (ASAM 2015)) for use in an EMR.   
Measure 1.   Demonstrate that the OUD -CDS is functional and accurate through:  
a) Testing in the EMR test environment,  
b) Chart audit validation of CDS output, and  
c) Approval of the tool by [CONTACT_360300][INVESTIGATOR_360256].  
2) To descriptively analyze PCP acceptability, satisfaction and use rates high enough to 
demonstrate proof of concept  
Measure 2A .  By [CONTACT_2671] 6 -month pi[INVESTIGATOR_52393], the monthly PCP use rate of the 
CDS for targeted high -risk patient encounters for  PCPs with CDS access will be >60%.   
Measure 2B .  By [CONTACT_2671] 6 -month pi[INVESTIGATOR_52393], >60% of PCPs with CDS access 
will report feeling confident in assessing and treating OUD  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 12  
 Measure 2C . At the end of the 6 -month pi[INVESTIGATOR_52393], >80% of PCPs with CDS access 
will rate the OUD- CDS >4 on a 5- point Likert scale of likeliness to recommend use of 
the tool to their colleagues.  
5.2 Secondary Objective(s)   
We will examine the usefulness of the OUD -CDS tool by [CONTACT_178537]- and post -intervention 
rates of screening for OUD in high -risk patients,  Tobacco, Alcohol, Prescription Medication, and 
Other Substance Use (TAPS)  use, OUD diagnosis, use of medication -assisted therapy, as well 
as treatment referral patterns, for 3 groups of PCPs: (1) those with CDS access and 
buprenorphine certification, (2) PCPs with CDS access but without buprenorphine certification, 
and (3) PCPs without CDS access.   
 
Where possible, we will structure these secondary outcome measures to be similar to nationally -
used clinical quality measures, such as:  
a) Initiation of pharmacotherapy upon new epi[INVESTIGATOR_360257] (Number of patients who 
receive at least 1 prescription for MAT  within 30 days following index visit with a 
diagnosis of OUD, divided by [CONTACT_360301] 60- day clean period without OUD documentation)(Washington 
Circle Group; DHHS 2015)  
b) Maintenance pharmacotherapy for OUD (patients who receive at least 30 days’ treatment with buprenorphine or naltrexone for OUD, divided by [CONTACT_360302] a diagnosis of OUD during the 6- month pi[INVESTIGATOR_32731])(American Psychiatric Association; 
DHHS 2015)  
6.0 STUDY DESIGN   
6.1 Overview of Study Design   
This 24- month pi[INVESTIGATOR_360258] -CDS into an EMR 
environment. This  will be an iterative process with input from addiction specialists and PCPs to 
make sure bugs that may arise during clinical implementation are identified and corrected. We anticipate that  programming the CDS into the EMR will take 12 months to complete.  
Upon completion of the progra mming phase, the OUD -CDS will be tested in multiple ways: 1) We 
will test the algorithms using real patient data in the EMR testing environment, 2) We will run the algorithms in the background of the production EMR environment without PCP displays, testing primarily data capture and operability, 3) We will pi[INVESTIGATOR_360259] -CDS with one or more providers 
with extensive experience in OUD care.  
Once live EMR assessment has been completed and any programming adjustments made, the 
OUD- CDS will be deployed for all PCPs with CDS access at PNMG and HPMG. Confidence in 
assessing and treating OUD prior to and [ADDRESS_449118] of the OUD -CDS on OUD identification and care. Automatic 
identification of eligible patients is done by [CONTACT_46251] -CDS algorithms, independent of any PCP 
actions.  
7.0 STUDY POPULATION   
We will recruit 16 non-waivered PCPs from multiple clinics to receive access to the OUD -CDS  (8 
MDs and 8 nurse practitioners (NPs) or physician assistants (PAs)) , as well as  16 PCPs from 
multiple clinics who will not receive access to the OU D-CDS  (8 MDs and 8 NPs/PAs) . Additionally, 
all 11 waivered PCPs (10 MDs, 1 NP) will be invited to participate and will receive access to the 
OUD- CDS.  All PCPs will complete baseline and 6- month surveys; PCPs with access to the OUD -
CDS will also be asked and incentivized to submit feedback about the CDS via the feedback tab 
in the CDS. Including multiple PCPs across multiple clinics, including both MDs as well as PAs 
and NPs,  will provide a better understanding of the feasibility and usefulness of the OUD -CDS 
across different providers, locations and patient populations.  
7.1 Participant Inclusion Criteria   
Eligible clinicians will:  
a) Be an MD, D octor of Osteopathy, Nurse Practitioner or Physician’s Assistant engaged in 
independent primary care of adults   
b) Have at least schedule 3 DEA prescribing privileges  
c) Voluntarily provide written informed consent to participate in this study  
7.[ADDRESS_449119] buprenorphine waivers, as they will be able to use the entirety of the OUD -CDS tool. 
In our invitation to participate in the study, we will inform PCPs that they will receive $150 (PCPs without CDS access) to $300 (PCPs with CDS access) each to compensate them for their time to complete electronically administered surveys at the beginning and end of the 6- month pi[INVESTIGATOR_360260] (PCPs with or without CDS access) and submission of feedback via the 
feedback tab in the CDS itself (PCPs who have access to the CDS). Approximately half of 
recruited PCPs will receive  access to the OUD -CDS; all PCPs with buprenorphine certification 
will be allotted to this group. Approximately half of recruited PCPs will not receive OUD -CDS 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 14  
 access. PCPs without buprenorphine certification will be randomized to receive or not receive 
access to the CDS.  
Recruitment diagram:   
Phase 1:
18 Months
Phase 2: 
6 Months
Phase 3:
6 Months
Translating the White Paper to an Epic compatible 
CDS and Building and Testing the CDS
Recruit PCPs at HP and PN
16 MDs , 16 NPs/PAs
All 11 waivered PCPs
11 PCPs with buprenorphine 
waiver : all will be assigned to 
arm with CDS access
32 PCPs without 
buprenorphine waiver : 
randomly assigned to arms 
with or without  CDS acces
16 non-waivered PCPs 
(8 MDs , 8 PAs/NPs)
Up to 11 waivered PCPs (10 
MDs , 1 NP)
16 non-waivered PCPs 
(8 MDs , 8 PAs/NPs)
All PCPs complete baseline survey
6-month pi[INVESTIGATOR_360261]
 
8.[ADDRESS_449120] of directors. The new organization 
includes a multispecialty group practice of more than 1,700 physicians , seven hospi[INVESTIGATOR_600] , 47 
primary care clinics , 22 urgent care locations , 22 dental clinics , and numerous specialty practices 
in Minnesota and western Wisconsin.  The majority of HPMG and PNMG patients (>80%) have 
commercial health insurance, while approximately 6% are insured via Medicare and 4% via 
Medicaid.  HPMG and PNMG offer outpatient primary and specialty addiction care, day programs, 
partial hospi[INVESTIGATOR_360262].  The medical groups refer out for methadone maintenance.  
PCPs who practice at least half -time and who have at least schedule [ADDRESS_449121] half of 2017 across HPMG and PNMG .  
9.0 OUTCOME MEASURES   
9.1 Primary Outcome Measure  
Primary Aims:  
1) To program an OUD -CDS tool based on a NIDA- Blending Initiative white paper “Clinical 
Decision Support for Opi[INVESTIGATOR_71081]: Working Group Report” and national guidelines 
(VA (VA 2015), ASAM (ASAM 2015)) for use in an EMR.   
Measure 1.  Demonstrate that the OUD -CDS is functional and accurate through:  
a) Testing in the EMR test environment,  
b) Chart audit validation of CDS output, and  
c) Approval of the tool by [CONTACT_360300][INVESTIGATOR_360256].  
2) To descriptively analyze PCP acceptability, satisfaction and use rates high enough to 
demonstrate proof of concept  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 16  
 Measure 2A .  By [CONTACT_2671] 6- month pi[INVESTIGATOR_52393], the monthly PCP use rate of 
the CDS for targeted high- risk patient encounters for PCPs with CDS access will be 
>60%.  
Measure 2B .  By [CONTACT_2671] 6 -month pi[INVESTIGATOR_52393], >60% of PCPs with CDS 
access will report feeling confident in assessing and treating OUD  
Measure 2C . At the end of the 6 -month pi[INVESTIGATOR_52393], >80% of PCPs with CDS access 
will rate the OUD- CDS > [ADDRESS_449122]-intervention rates of screening for OUD in high- risk patients, TAPS use, OUD diagnosis, use 
of medication- assisted therapy, as well as treatment referral patterns, for 3 groups  of PCPs: (1) 
those with CDS access and buprenorphine certification, (2) PCPs with CDS access but without 
buprenorphine certification, and (3) PCPs without CDS access.    
Where possible, we will structure these secondary outcome measures to be similar to na tionally -
used clinical quality measures, such as:  
a) Initiation of pharmacotherapy upon new epi[INVESTIGATOR_360257] (Number of patients who receive at least 1 prescription for MAT within 30 days following index visit with a diagnosis of OUD, 
divided by [CONTACT_360301] 60-day clean period without OUD documentation)(Washington Circle Group; DHHS 2015)  
b) Maintenance pharmacotherapy for OUD (patients who receive at least 30 days’ treatment with buprenorphine or naltrexone for OUD, divided by [CONTACT_360302] a diagnosis of 
OUD during the 6- month pi[INVESTIGATOR_32731])(American Psychiatric Association; DHHS 2015)  
9.2 Other Outcome Measures  
MAT has been shown to reduce adverse outcomes, such as overdoses, emergency room visi ts, 
hospi[INVESTIGATOR_360263] , for patients with OUD  (Mohlman 2016; WHO 2013; Cornish 2010 ; 
Lo-Ciganic 2016). As a quality measure to inform future implementation studies of this OUD -CDS, 
we will collect and report available EHR data  on overdoses, ER visits, hospi[INVESTIGATOR_360264]- risk for OUD or as having been diagnosed with 
and/or treated for OUD.  This data will be collected for patients of  both PCPs with and without CDS 
access; f or PCPs without CDS access, the CDS will still be collecting data behind the scenes 
without any displays to the PCP.   
10.0 STUDY PROCEDURES   
10.1 Phase  1: Translating the White Paper to an Epic -compatible CDS and 
Building and Testing the CDS (15 months)  
10.1.[ADDRESS_449123] team will meet frequ ently (on average weekly) throughout the duration of this 
project.  
10.1.[ADDRESS_449124] one other substance use disorder or uncontrolled behavioral health conditions.  
6. The CDS programs will then be designed to fit into the primary care clinic workfl ows. As 
envisioned currently: (a) When the rooming staff enter a blood pressure and close the vitals section in Epic, this triggers communication between Epic and the web server and the OUD CDS will run the algorithms. (b) For patients identified at high risk for OUD, a best practice advisory will display for the rooming staff to open and print the CDS.  The rooming staff will 
give the CDS to the PCP prior to the office visit so that the PCP is aware that the patient is 
potentially at risk for OUD and requires s creening, diagnosis and/or treatment. The PCP will 
then re- enter the CDS during the encounter. (c) We train both the PCP and rooming staff in 
these procedures and the importance of this workflow. (d) Use rates are monitored by [CONTACT_360303]. (e)  We will survey PCPs about the support staff and services they currently 
have in place and what kinds of support or staff they would like to see in place to further inform 
our study and implementation.  
7. We will program OUD clinical algorithms in a web- based platform and ensure secure and 
timely communication between the web- based platform  and HealthPartners’ Epi[INVESTIGATOR_360265]  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 18  
 (Epic; Verona, WI) . Steps [ADDRESS_449125] use of the CDS for screening patients identified at high risk for OUD.  We will identify 
the criteria for automatic deployment in an iterative process, informed by [CONTACT_360304] a recent big data study on the risk 
of OUD in patients receiving an initial opi[INVESTIGATOR_16447] (Cochran 2014) . We anticipate a 
waterfall approach that may, for example, identify patients with (1) one inpatient or two 
outpatient diagnoses of OUD in the past 2 years, (2) [ADDRESS_449126] 2 years, and (3) diagnoses of non -opi[INVESTIGATOR_360266], including 
sedative/hypnotics , cocaine, or cannabis.  The process to trigger the CDS will be modified 
based on feedback we receive from PCPs in the pi[INVESTIGATOR_360267].  PCPs will be encouraged to open the CDS for patients identified by [CONTACT_360305], Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool specific to OUD  
(McNeely 2016)  that will be programmed as a smartform within Epic . 
9. The programs have many layers of abstraction achieved by [CONTACT_360306] a specific task. The layer above it can work in generalizations without specific knowledge of the tasks performed in the previous layer. The top layer of this stack will run the high -level decisions 
involved in the CDS. Design decisions are also based on what type of information is needed 
and where and when it is available for extraction from the E MR. In cer tain cases, the data 
required are not in the E MR and we will have to make alternate plans to collect such data from 
the patient  and/or provider.   
10. We will design provider and patient print-outs for the OUD -CDS  that PCPs can use as shared -
decision- making tools with their patients.  Traditionally , the provider print -out has had more 
details and specific treatment suggestions, while the patient version has included the same 
basic information without relying on high literacy or numeracy.  However, we have found that 
some PCPs prefer to review the provider print- out with patients, and keep this in mind as we 
design these forms.   
10.1.[ADDRESS_449127] three clinicians, observing them using the CDS in person in the production 
or testing environment. We will use a “talk or think aloud” protocol to identify any screen design or other usability issues.  
18. During these testing phases, we will test output of the care algorithms in batch process. We 
continuously validate collected data and closely monitor usage , traffic  and accuracy.  
19. Infrastructure and data security will be maintained by [CONTACT_360307] -wide scans and 
by [CONTACT_360308]. Systems will be constantly monitored for errors.   
20. We will mod ify the smart sets and active guidelines as needed to provide actionable order sets 
for medications, labs, and referrals, automatic population of patient instructions, and facilitation of diagnostic coding based on algorithmic suggestions.  
21. We will develop reports to monitor usage at the provider level, provide feedback to PCPs and trouble- shoot low use rates . 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 20  
 22. We will recruit PCPs in -person and via emailed invitations approved by [CONTACT_1201].   
23. We will assign PCPs to receive or not receive OUD access.   
24. We will assess confidence in assessing and treating OUD at baseline via an electronic survey  
for PCPs with and without CDS access  
10.2 Phase  2: De ploying and Testing the CDS in Primary Care (6 months)  
25. We will deploy OUD- CDS to approximately half of consented PCPs   
26. We will obtain feedback on OUD -CDS from PCPs  in real -time in association with patient 
encounters  via the feedback tab in the CDS  and update the algorithms when indicated by [CONTACT_360309]  
27. We will measure and report use rates of the OUD -CDS at targeted visits  by [CONTACT_360310]- shoot low use rates . For PCPs with use rates <60% of targeted visits, we will meet 
with the PCP to better understand why use rates are low, trouble- shoot any identified barriers, 
and encourage increased use.   
28. We will update and troubleshoot the CDS algorithms as needed, based on internal monitoring, 
provider feedback, FDA changes in treatment indications, or changes in the clinical evidence base or guideline recommendations.   
10.3 Phase  3: Analysis and Reporting (3 months)  
29. After the 6 -month pi[INVESTIGATOR_32731], we will reassess provider confidence in assessing and treating 
OUD for PCPs  with and without CDS access, and obtai n feedback on OUD- CDS  usability and 
satisfaction from PCPs with CDS access, via electronic survey  
30. Data will be consolidated, cleaned and analyzed  
31. We will disseminate findings locally and nationally, and submit manuscripts for publication  
10.4 Informed Consent P rocedures for Participants  
We are asking  PCPs to give informed consent to use the OUD -CDS on a voluntary and optional 
basis (if in the group of PCPs who are assigned to receive CDS access) and complete the pre- 
and post -intervention surveys. As the OUD- CDS is essentially operationalizing national and 
regional clinical guidelines, we will not be consenting PCPs  to specifically change any clinical 
behavior related to managing patients with OUD . There is a small but important risk that the OUD -
CDS could  provide the wrong treatment advice at the wrong time.  As with other clinical decision 
tools, the CDS makes suggestions for patient care and is meant to supplement but not supersede the PCP’s clinical judgment.  This point is made clear in the training, in the consent, and on the 
provider display for the CDS.  We will seek an IRB waiver of written informed consent f or primary 
care clinic patients , as the CD S does not recommend any new care procedures and is being 
applied within the EMR as an aid to the PCP  to facilitate recommended standards of care . 
HealthPartners IRB has granted waivers for other studies of CDS in the past. 
10.[ADDRESS_449128] buprenorphine certification 
will be randomized to receive or not receive access to the OUD -CDS. 
10.8 Treatment/Intervent ion  
The intervention is the availability of the OUD -CDS to approximately half of enrolled PCPs.   
10.[ADDRESS_449129] follow -up survey information from PCPs 6 months after the OUD -CDS go -live date.  
During the 6- month intervention phase, we will be monitoring PCP use of the CDS, providing use 
rate reports for PCPs, and contact[CONTACT_360311] 60% to trouble- shoot low 
use and understand any barriers to use. 
10.13  Blinding  
This study is not blinded. All consented PCPs will be aware of their access or lack of access to 
the OUD -CDS. 
10.14  Participant Reimbursement   
PCPs will be reimbursed $150 (PCPs without CDS access) to $300 (PCPs with CDS access) for 
their time to complete pre- and post -implementation surveys, and, for PCPs who have access to 
the CDS, to submit feedback via the feedback t ab in the CDS . 
10.[ADDRESS_449130] the PCP directly to determine any barriers 
to use and to encourage increased use.  
11.0 STUDY ASSESSMENTS  
11.1 Study Assessments  
11.1.1  PCP Surveys  
Prior to going live with the OUD- CDS, PCPs with and without CDS access will complete a  baseline 
survey via a unique emailed link. The survey will be administered via the Survey Research Center 
at HealthPartners Institute via RedCap, and will be maintained in a secure HealthPartners server.  
This initial survey will be focused on PCP confidence in their ability to screen for, assess, 
diagnose, treat and refer patients with OUD appropriately, assessed via 5- point Likert scales . 
After the 6 -month intervention, all PCPs will again be surveyed about their confidence in OUD 
care.  Additionally, the PCPs with CDS access will complete survey questions specific to the OUD -
CDS , including questions regarding usability, accuracy, and provider likelihood to recommend the 
tool. A draft of specific items in the surveys follows.  
SURVEY DRAFT  
1. What is your primary clinic ? 
 
2. What is your age ? 
 
3. What is your g ender  
 
4. With which r ace/ethnicity  do you identify? 
o Asian  
o Hispanic  
o Native American/Alaskan Native 
o Non-Hispanic black  
o Pacific Is lander/Native Hawaiian  
o White  
o Mixed race or other  
o Prefer not to answer  
 
  
 NIDA CTN Protocol  -[ADDRESS_449131] you been in practice following residency or fellowship? 
o 0-5 
o 6-10 
o 11-15 
o 16-20 
o 21+ 
 
6. What is your m edical specialty ? 
o Family Practice  
o Internal Medicine  
o Med Peds  
o Other (please specify)  
 
7. On average, how many days a week do you see patients in clinic?  
o 0 
o 1 
o 2  
o 3 
o 4 
o 5 or more  
 
Answer the questions below about your knowledge and approach to management of patients 
with Opi[INVESTIGATOR_2442] (OUD). Choose only one answer.  
8. How often do you formally assess patients for opi[INVESTIGATOR_2427] (OUD)?  
 
Very often  Often  Sometimes  Occasionally  Never  
 
9. How confident do you feel about  screenin g your patients for OUD? 
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
10. How often do you provide treatment or refer  your patients  for treatmen t of OUD?  
Very often  Often  Sometimes  Occasionally  Never  
 
11. How confident are you at  diagnosing  patients with OUD?  
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 24  
 12. How confident are you at  treating your patients with medications  such as buprenorphine or 
naltrexone  for OUD?   
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
13. How confident are you at  knowing when to refer  your patients with OUD for treatment by 
[CONTACT_360312] ? 
 
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
14.  (Skip if certified in buprenorphine prescribing) To what extent do you agree or disagree with 
the following statement: The availability of EHR- integrated clinical decision support for how 
to use buprenorphine and/or naloxone and manage OUD would make it more likely that I 
would become a certified buprenorphine prescriber.   
Strongly agree   Somewhat 
Agree  Somewhat 
Disagree  Strongly 
disagree  
 
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 25  
 15. Please rate your ability to effectively manage patients with the following treatment 
strategies:  
 High ability 
(on par with 
subspecialist
s) Moderately 
high ability  Adequate 
ability  Some ability;  
could use 
improvement  Low 
ability  
Brief 
motivational 
counseling  1 2 3 4 5 
Overdose 
prevention  1 2 3 4 5 
Extended -
release 
naltrexone 
(Vivitrol)  1 2 3 4 5 
Buprenorphine 
(as 
monotherapy 
or in 
combination 
with naloxone 
(Suboxone))  [ADDRESS_449132] -Implementation Survey 
Answer the questions below about your knowledge and approach to management of patients 
with Opi[INVESTIGATOR_2442] (OUD). Choose only one answer.  
1. How often do you formally assess patients for opi[INVESTIGATOR_2427] (OUD)?  
Very often  Often  Sometimes  Occasionally  Never  
 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 26  
 2. How confident do you feel about  screenin g your patients for OUD? 
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
3. How often do you provide treatment or refer  your patients  for treatmen t of OUD?  
Very often  Often  Sometimes  Occasionally  Never  
 
4. How confident are you at  diagnosing  patients with OUD?  
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
5. How confident are you at  treating your patients with medications  such as buprenorphine or 
naltrexone  for OUD?   
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
6. How confident are you at  knowing when to refer  your patients with OUD for treatment by 
[CONTACT_360312] ?  
Very confident  Moderately  
confident  Somewhat  
confident  Not at all  
confident  
 
7. (Skip if certified in buprenorphine prescri bing) To what extent do you agree or disagree with 
the following state ment: The availability of EHR- integrated clinical decision support for how 
to use buprenorphine and/or naloxone and manage OUD would make it more likely that I 
would become a certified buprenorphine prescriber.   
Strongly agree  Agree  Disagree  Strongly 
disagree  
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 27  
 8. Please rate your ability to effectively manage patients with the following treatment 
strategies:  
 High ability 
(on par with 
subspecialist
s) Moderately 
high ability  Adequate 
ability  Some ability;  
could use 
improvement  Low 
ability  
Brief 
motivational 
counseling  1 2 3 4 5 
Overdose 
prevention  1 2 3 4 5 
Extended -
release 
naltrexone 
(Vivitrol)  1 2 3 4 5 
Buprenorphine 
(as 
monotherapy 
or in 
combination 
with naloxone 
(Suboxone))  1 2 3 4 5 
Referral for 
methadone or 
other 
treatment  1 2 3 4 5 
 
 
NOTE: **These questions will only be present in the post (6- month) surveys  for 
PCPs with CDS a ccess**  
Please answer the questions below concerning work flow and ease of use of the Opi[INVESTIGATOR_360268] .  
9. How likely are you to recommend Opi[INVESTIGATOR_360269] a colleague?   
 NIDA CTN Protocol  -[ADDRESS_449133] features?  
Feature  Very 
useful  Moderately 
useful  Somewhat  
useful  Slightly 
useful  Not at all useful  
Screening tools (TAPS)       
Diagnosis tools       
Prescribing overdose 
kits      
Guidance for screening 
for comorbidities such 
as alcohol use disorder, 
hepatitis, pregnancy       
Deciding which 
treatment approach is best for the patient (medication -assisted 
therapy by [CONTACT_360313], referral to an addiction specialists for 
medication -assisted 
therapy, safer use, further discussion, etc.)       
Deciding between 
different strategies of 
medication -assisted      
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 30  
 therapy (naltrexone vs. 
buprenorphine vs. 
methadone)  
Safety alerts for 
drug/drug interactions       
Urine drug screen 
testing reminders       
19. How could we make Opi[INVESTIGATOR_360270]?  
________________________________________________________________________ 
________________________________________________________________________ 
20. Do you have any other feedback you’d like to share, or ways in which you think Opi[INVESTIGATOR_360271]?  
________________________________________________________________________ 
 
Thank you for your participation. Your input is greatly appreciated!  
 
11.[ADDRESS_449134] PCPs who fall below a use rate of 60% to determine if there are any 
issues or concerns with the OUD -CDS and to problem -solve any barriers to use.  
11.3 General Measures   
11.3.1  Inclusion/Exclusion  
Inclusion criteria for PCPs:  
a) An MD, DO, NP, or PA engaging in independent primary care of adults  
b) At least schedule 3 DEA prescribing privileges  
c) Voluntarily consent to participation  
 
Exclusion criteria for PCPs:  
a) Less than half -time clinical primary care responsibilities  
 NIDA CTN Protocol  -[ADDRESS_449135] of consented PCPs (both  those who have CDS access and those who do not ) 
on a secure server at HealthPartners . This list will include the PCP name, primary care clinic 
name, phone number of the clinic and provider email address.   
11.[ADDRESS_449136] age, gender, race/ethnicity, years of practice and medical specialty (primary care 
vs. internal medicine) for PCP participants.  Patient -level data required to assess study objectives 
will be stored in a secure analytic database.   
11.[ADDRESS_449137] Health Care Systems Research Network Virtual 
Data Warehouse data elements  (Ross TR 2014).   
11.7 End of Medication/End of Treatment Form  
Not applicable.   
11.8 Study Completion Form  
Not applicable.    
11.9 Measures of Primary and Secondary Outcomes  
Primary Aims:  
1) To program an OUD -CDS tool based on a NIDA- Blending Initiative white paper “Clinical 
Decision Support for Opi[INVESTIGATOR_71081]: Working Group Report” and national guidelines 
(VA (VA 2015), ASAM (ASAM 2015)) for use in an EMR.   
Measure 1.  Demonstrate that the OUD -CDS is functional and accurate through:  
a) Testing in the EMR test environment,  
b) Chart audit validation of CDS output, and  
c) Approval of the tool by [CONTACT_360300][INVESTIGATOR_360272].  
2) To descriptively analyze PCP acceptability, satisfaction and use rates high enough to demonstrate proof of concept  
Measure 2A .  By [CONTACT_2671] 6- month pi[INVESTIGATOR_52393], the monthly PCP use rate of the 
CDS for targeted high -risk patient encounters for PCPs with CDS access will be >60%.  
Measure 2B .  By [CONTACT_2671] 6- month pi[INVESTIGATOR_52393], >60% of PCPs with CDS access 
will report feeling confident in assessing and treating OUD  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 32  
 Measure 2C . At the end of the 6 -month pi[INVESTIGATOR_52393], >80% of PCPs with CDS access 
will rate the OUD- CDS >[ADDRESS_449138]-intervention rates of screening for OUD in high- risk patients, TAPS use, OUD diagnosis, use 
of medication- assisted therapy, as well as treatment referral patterns, for 3 groups of PCPs: (1) 
those with CDS access and buprenorphine certification, (2) PCPs with CDS access but without 
buprenorphine certification, and (3) PCPs without CDS access. 
 
11.10  Clinical and Safety Assessments   
11.10.1  Adverse Events (AEs) and Serious Adverse Events (SAEs)  
This study is being conducted at the provider level using CDS prompts for evidence- based best 
practice standards related to OUD. Prior to implementation, we will train all intervention PCPs and 
their rooming staff on the importance of helpi[INVESTIGATOR_360273]- misses that 
may be related to the EHR or CDS.  We will systematically educate them in identification of 
potential safety events and near- misses and appropriate use of the Feedback button in the CDS 
or email to promptly notify us about such events. We will also ask PCPs to notify us of any clinical 
situations where their clinical judgment differs from the CDS .   
 Use of the Feedback button automatically generates an email that is sent to Drs. Rossom and 
Sperl -Hillen and the web programming team . The research team then discusses this feedback 
and any necessary actions, and connects with the PCP to answer the question, discuss steps 
taken to address the issue, or gather additional information if needed to further trouble -shoot . 
PCPs will be asked to submit feedback any time their clinical judgment is inconsistent with the 
CDS tool. Additionally, the emails of Drs. Rossom and Sperl- Hillen are listed on the CDS interface 
for providers, and PCPs are encouraged to contact [CONTACT_360314]’d rather not use the feedback tab in the OUD -CDS.  This feedback will be provided to the 
DSMB  twice during the study period or at a frequency the DSMB  requests.    
 
11.[ADDRESS_449139] PC Ps who 
fall below a use rate of 60% to determine if there are any issues or concerns with the OUD -CDS 
and problem -solve any barriers to use. We will consider the OUD -CDS to be effectively 
implemented if it is used by [CONTACT_360315] 60 % of targeted patient encounters.   
11.[ADDRESS_449140] completed such trainings at in- person 
lunch meetings with clinic personnel, but will also consider web- based training s depending on 
clinic  leadership preference.   
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 34  
 13.0 STATISTICAL DESIGN AND ANALYSE S  
13.1 General Design   
13.1.1  Study Hypothesis   
A web-based EMR -integrated point -of-care CDS  tool for OUD is both feasible and usable in the 
primary care setting.  
13.2 Primary and Secondary Outcomes (Endpoints)   
Primary Aims:  
1) To program an OUD -CDS tool based on a NIDA -Blending Initiative white paper “Clinical 
Decision Support for Opi[INVESTIGATOR_71081]: Working Group Report” and national guidelines 
(VA (VA 2015), ASAM (ASAM 2015)) for use in an EMR.   
Measure 1.  Demonstrate that  the OUD -CDS is functional and accurate through:  
a) Testing in the EMR test environment,  
b) Chart audit validation of CDS output, and  
c) Approval of the tool by [CONTACT_360300][INVESTIGATOR_360256].  
2) To descriptively analyze PCP acceptability, satisfaction and use rates high enough to demonstrate proof of concept  
Measure 2A .  By [CONTACT_2671] 6- month pi[INVESTIGATOR_52393], the monthly PCP use rate of the 
CDS for targeted high -risk patient encounters for PCPs with CDS access will be >60%.   
Measure 2B .  By [CONTACT_2671] 6- month pi[INVESTIGATOR_52393], >60% of PCPs with CDS access 
will report feeling confident in assessing and treating OUD  
Measure 2C . At the end of the 6 -month pi[INVESTIGATOR_52393], >80% of PCPs with CDS access 
will rate the OUD- CDS >[ADDRESS_449141]-intervention rates of screening for OUD in high- risk patients, TAPS use, OUD diagnosis, use 
of medication- assisted therapy, as well as treatment referral patterns, for 3 groups of PCPs: (1) 
those with CDS access and buprenorphine certification, (2) PCPs with CDS access but without buprenorphine certification, and (3) PCPs without CDS access.     
14.[ADDRESS_449142] buprenorphine waivers, as they will be able 
to use the entirety of the OUD -CDS tool.  In our invitation to participate in the study, we will inform 
PCPs that they  will receive $150 (PCPs without CDS access) or $300 (PCPs with CDS access) 
each to compensate them for their time in completing emailed surveys at the beginning and end 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 35  
 of the 6 -month pi[INVESTIGATOR_360274] ( all PCPs ), and for their time in submitting feedback via 
the feedback tab in the CDS (PCPs with access to the CDS) . 
15.[ADDRESS_449143] -intervention surveys of provider confidence in OUD assessment and treatment as 
well as satisfaction and usability of the OUD- CDS will be described. 
16.3 Significance Testing   
This pi[INVESTIGATOR_360275]- CDS feasibility and usability does not entail statistical testing or power 
calculations. Provider characteristics, patient character istics, and OUD- CDS use rates will be 
tracked and descri bed. 
16.4 Types of Analyses  
Provider characteristics, patient characteri stics, and OUD -CDS use rates  will be tracked and 
descriptively analyzed.  
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 36  
 16.5 Interim Analys is  
Not applicable for a pi[INVESTIGATOR_360276] 6 months.   
16.6 Exploratory Analysis   
MAT has been shown to reduce adverse outcomes, such as overdoses, hospi[INVESTIGATOR_360277], for patients with OUD (Mohlman 2016; WHO 2013).  As a quality  measure to inform future 
implementation s tudies of this OUD -CDS, we will collect  available EHR data to examine 
overdoses, ER visits, hospi[INVESTIGATOR_360278].  While this information will likely not be useful for statistical considerations, 
trends observed could be hypotheses -generating and inform future study needs. 
16.[ADDRESS_449144] CDS access an incentive of $[ADDRESS_449145] CDS access an incentive of $300 to complete baseline 
and 6- month survey s and submit feedback via the CDS feedback tab.  
16.8 Demographic and Baseline Characteristics  
Baseline demographic and practice variables (e.g., years in practice, size of patient panel, etc.) 
will be summarized for PCPs enrolled in this study.  
16.[ADDRESS_449146] of care in OUD treatment. PCPs are trained 
that, as with other CDS  tools, the OUD -CDS is meant to supplement but not supersede clinical 
judgment.  PCPs can choose to follow or not follow the guidance of the CDS at any given time for 
any given patient encounter, and PCPs are trained to let the research team know via the 
Feedback tab in the CDS when their clinical judgment is inconsistent with the CDS recommendations.  This feedback will be monitored by [CONTACT_46260].  
An independent CTN DSMB will monitor this study.  The DSMB will communicate regarding what type of reports will be needed, as well as frequency.    
17.0 REGULATORY COMPLIANCE AND SAFETY  
17.1 Regu latory Compliance   
This study will be conducted in accordance with the current version of the protocol, in accordance with the ethical principles outlined in the Declaration of Helsinki, International Conference on 
Harmonization Good Clinical Practice (GCP) Guidelines, and all other applicable regulatory 
requirements.   
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 37  
 17.2 Statement of Compliance   
This trial will be conducted in compliance with the appropriate protocol, current Good Clinical 
Practice (GCP), the principles of the Declaration of Helsinki, and all other applicable regulatory 
requirements.  The participating clinic sites are all within the HealthPartners system and therefore, 
protocol review, consent forms, and other pertinent regulatory materials will be reviewed by 
[CONTACT_360316]. W hile the 
intervention is only [ADDRESS_449147] Approval   
Prior to initiating the study, site investigators will  obtain written HealthPartners’ IRB approval to 
conduct the study. Should substantive changes to the study protocol become necessary, protocol 
amendments will be submitted in writing by [CONTACT_9905]. In addition, the IRB will approve all consent forms and recruitment and survey 
materials.  Progre ss reports will be submitted to the IRB annually or at a frequency requested by 
[CONTACT_360317]. The lead investigator is 
responsible for maintaining in her research files copi[INVESTIGATOR_360279]/IEC approval notice and 
IRB-approved consent document(s), including approval for all protocol modifications. These 
materials must be available at any time for audit.  
17.[ADDRESS_449148] participants’ participation in the trial. The participant will be informed that their participation is voluntary and 
they may withdraw from the study at any time, for any reason without penalty. Individuals who 
refuse to participate or who withdraw from the study will be treated without prejudice. Study sites will be responsible for maintaining signed consent forms as source documents for quality assurance review and regulatory compliance. 
17.[ADDRESS_449149] periodic chart audits to ensure that data collected by [CONTACT_941] C DS is accurate 
and c omplete. Drs. Rossom and Sperl -Hillen will also monitor all PCP feedback during the 
intervention, work together with the programming team to determine whether the CDS needs to be altered to address the issues raised in the feedback, and make adjustments to  the CDS as 
clinically indicated.  
17.6 Confidentiality   
Confidentiality will be maintained in accordance with all applicable federal and state regulations. By [CONTACT_360318], Ethical Review Committee, or similar expert committee; affiliated institution; and employees only under an appropriate understanding of confidentiality with such board or committee, affiliated institution and employees. Participant records will be held confidential by [CONTACT_360319], secure storage of any documents that have participant identifiers, and secure computing procedures for entering and  transferring electronic data.  
17.[ADDRESS_449150] (HIPAA)   
Participants in this study are answering surveys regarding usability of an OUD -CDS. No personal 
health information is collected from participants as a part of this study. The OUD -CDS will be used 
by [CONTACT_360320]. The CDS has automated algorithms to identify 
patients for whom it may be appropriate to use the OUD -CDS.  These patients are not participants 
in the research but their data is utilized by [CONTACT_46251] -CDS. HIPAA itself makes specific provision 
for waiver of authorization to use PHI for research recruitment purposes under some specific 
conditions, all of which this study meets: “For research uses and disclosures of PHI, an IRB or privacy board may approve a waiver or an alteration of the authorization requirement in whole or 
in part. A complete waiver occurs when the IRB or privacy board determines that no authorization 
is required for a covered entity to use and disclose PHI for a particular research project. A partial waiver of authorization occurs when an IRB or privacy board determines that a covered entity does not need authorization for all PHI uses and disclosures for research purposes, such as disclos ing PHI for research recruitment purposes. An IRB or privacy board may also approve a 
request that removes some PHI, but not all, or alters the requirements for an authorization (an alteration).” See:  
 http://privacyruleandresearch.nih.gov/pr_08.asp#8c
. 
17.8 Investigator Assurances  
Health Partners maintains a current Federal Wide Assurance (FWA) with the DHHS Office for 
Human Research Protection setting forth the commitment of t he organization to establish 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 39  
 appropriate policies and procedures for the protection of human research subjects. This 
documentation will be sent to NIDA or its designee. Research covered by [CONTACT_360321] (45 CFR 46.103(b) and (f)). Prior to initiating the study, the principal investigator [INVESTIGATOR_877] a protocol signature [CONTACT_3264], providing assurances tha t the study will be performed according to the standards stipulated therein.  
17.[ADDRESS_449151] met their institutional financial disclosure requirements.  
17.10  DEA Registration  (Component  for medication studies using controlled 
substances studies – use if applicable)  
All enrolled PCPs will have appropriate DEA registration. As this is required for them to be able to prescribe medications as part of their medical practice at Park Nicollet  and HealthPartners  
clinics , research staff will not verify or monitor DEA registration status of participants.  We will not 
be receiving any shipments of study drug.  
17.11  IND Requirements  (Component for IND studies – use if applicable)  
Not applicable.   
17.[ADDRESS_449152] access 
to the CDS  and 16  PCPs who will not, and that these PCPs  will be generally representative of the 
HPMG and PNMG provider pool s in terms of gender and racial/ethnic distribution.  
  
 NIDA CTN Protocol  -[ADDRESS_449153] or outcome of the trial or increase risk to study participants. At the completion of the trial, the Lead Investigator will provide a final report to the Sponsor.  
17.17  Audits   
The Sponsor has an obligation to ensure that this trial is conducted according to good research 
practice guidelines and may perform quality assurance audits for protocol compliance. The Lead 
Investigator and authorized staff from the NorthStar  Node; the National Institute on Drug Abuse 
Clinical Trials Network (NIDA CTN, the study sponsor); NIDA’s contracted agents, monitors or auditors; and other agencies such as the Department of Health and Human Services (HHS), the Office for Human Research P rotection (OHRP) and the sites’ Institutional Review Board may 
inspect research records for verification of data, compliance with federal guidelines on human participant research, and to assess participant safety.  
17.18  Study Documentation  
Study documentation includes all source documents, monitoring logs and appointment schedules, 
sponsor -investigator correspondence, and signed protocol and amendments, Ethics Review 
Committee or Institutional Review Committee correspondence and approved consent form and 
signed participant consent forms.  Source documents include all recordings of observations or 
notations of clinical activities and all reports and records necessary for the evaluation and reconstruction of the clinical research study. Whenever possible, the original recording of an 
observation should be retained as the source document; however, a photocopy is acceptable 
provided that it is a clear, legible, and exact duplication of the original document.  
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 41  
 17.19  Protocol Deviations   
Any departure from procedures and requirements outlined in the protocol will be classified as  
either a major or minor protocol deviation.  The difference between a major and minor protocol 
deviation has to do with the seriousness of the event and the corrective action required.  A minor 
protocol deviation is considered an action (or inaction) that by [CONTACT_200884], rights, or welfare of a study participant.  Major protocol deviations are departures that may compromise the participant safety, 
participant right s, inclusion/exclusion criteria or the integrity of study data and could be cause for 
corrective actions if not rectified or prevented from re- occurrence.   
 Since the intervention of this study is access to the OUD -CDS and pre - post-intervention surveys, 
we do not anticipate safety issues related to the participants or for the opportunity for protocol deviations . Because the OUD -CDS programming may have unanticipated bugs that  may lead the 
CDS  to recommend (or fail to recommend) a clinical action that is i nappropriate for a given patient, 
we will use a live “Feedback” tab that displays in the OUD -CDS to let the study team know of any 
questions or concerns with the CDS . This automatically generates an email that is sent to Drs. 
Rossom and Sperl- Hillen and the web programm ing team.  The research team will then discuss 
this feedback and any necessary actions, and will connect with the PCP to answer the question, 
discuss steps taken to address the issue, or gather additional information and further trouble-shoot.  Identification of protocol deviations  through this mechanism will be adjudicated by [CONTACT_360322] a corrective action plan for both major and minor deviations as appropriate.  
Those corrective action plans may be reviewed/approved by [CONTACT_360323]’s IRB.  All protocol deviations will be monitored at each site for (1) significance, (2) 
frequency, and (3) impact on the study objectives, to ensure that site performance does not compromise the integrity of the trial.   
17.[ADDRESS_449154] (DSMB)   
An independent CTN DSMB will monitor this study.  The DSMB will communicate regarding what type of reports will be needed, as well as frequency.  The CTN DSMB is responsible for conducting 
periodic reviews of accumulating safety and efficacy data. It will determine whether there is support for continuation of the trial, or evidence that study procedures should be changed, or if the trial should be halted, for reasons relating to the safety of the study participants, the efficacy of the treatment under study, or inadequate trial performance (e.g., poor recruitment). 
17.20.2  
Adverse Events (AEs)   
This study is being conducted at the provider level using CDS prompts for evidence- based best 
practice standards related to OUD. As such, we are not trying to change the standard of care for 
OUD in primary care, but rather to help PCPs achieve this standard of care in their care of patients with OUD.  To monitor usabilit y, PCPs will be instructed to use the “Feedback” tab that displays in 
the OUD -CDS to let the study team know of any questions or concerns with the CDS . In particular, 
PCPs are trained to let the research team know via the Feedback tab in the CDS when their 
 NIDA CTN Protocol  -[ADDRESS_449155] us directly with any questions or concerns if they’d rather not use the feedback tab in the OUD -CDS.  This PCP 
feedback will be provided to the DSMB  at a frequency the DSMB  requests.  
18.0 DATA MANAGEMENT   
Apart from data collected from the PCPs via surveys and feedback mechanisms, data for analysis 
will be largely collected by [CONTACT_46251]- CDS itself.  This web- based tool houses the algorithms, 
communicates with and displays within the EMR, and stores data required to assess study 
objectives will be retained in a secure analytic database at HealthPartners Institute. These data, 
supplemented by [CONTACT_360324], will be used to assess CDS use rates, MAT rates and referral 
patterns (described in secondary aim s). We will not be using Advantage eClinical to collect or 
house data, and as this is a pi[INVESTIGATOR_360280], we will not use a centralized Data 
and Statistics Center.   
18.1 Study Timeline  
CTN Protocol Milestone Expected Date 
Completed  Comments  Protocol  
Development Concept finalized      
      
Submit protocol including DSMP and informed consent in 
preparation for DSMB meeting (also - site selection plan, leadership 
plan, proposed budget, single IRB plan, recruitment and retention 
plan)  2/28/[ADDRESS_449156] one month prior to 
DSMB meeting.  
DSMB Meeting/Review  3/27/2017  *tentative target date, 
exploring what type of 
review required  
Full protocol reviewed and approved by [CONTACT_133312]  4/18/2017  * if significant changes 
are required following 
the DSMB meeting, 
dates will need to be 
adjusted  
Budget finalized  5/31/2017    Pi[INVESTIGATOR_360281]  4/18/2017  Assuming quick DSMB 
and CCTN feedback  
Lead Node initial Protocol IRB submission  3/1/2017    
Initial review of all Case Report Forms by [CONTACT_360325]  N/A   
IRB Protocol approval date  4/30/2017    
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 43  
 CTN Protocol Milestone Expected Date 
Completed  Comments  
Registration in clinicaltrials.gov website  5/15/2018    
      
Stage 1 (CDS Build)  6/6/2018    
Includes:   
Adapt OUD CDS whitepaper to CDS algorithms  
Program algorithms  
Create provider CDS interfaces  
Test algorithms in testing environment  
Recruit PCPs, administer baseline survey  
Pi[INVESTIGATOR_21087]/modify intervention with one provider with experience 
in OUD  assessment and treatment, and several les experienced 
providers     
      
Phase 2 (CDS Deployment)   11/7/2018    
Includes:  
Go Live: Active intervention phase  
Monitor CDS use with feedback  
Update and/or troubleshoot algorithms     
      
Phase 3 (Analysis and Reporting)  4/30/2019    
Includes:  
Conduct follow -up provider surveys  
Consolidate/analyze data to test hypotheses  
Dissemination activities, manuscript submission          
Final Study Report submitted to NIDA  4/30/2019    
Provide study results via clinicaltrials.gov website  
(at the end of a trial)  4/30/2019    
Primary outcome paper submitted to journal  4/30/2019    
Primary outcome paper accepted  8/31/2019    
Data posted on CTN's Public Data Share  10/31/2020    
 
19.0 PUBLICATIONS AND OTHER RIGHTS   
The authors agree to follow NIH’s policy requiring all investigators to submit or have submitted for 
them to the National Library of Medicine’s PubMed Central an electronic version of their final peer -
reviewed manuscripts upon acceptance for publication, to be made publically available no later 
than 12 months after the official date of publication.   
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 44  
 20.0 SIGNATURES   
 
SPONSOR’S REPRESENTATIVE (CCTN DESIGNEE)  
     
          
Printed Name   [CONTACT_360335] [CONTACT_9929]:  
• I am in receipt of version X of the protocol and agree to conduct this clinical study in 
accordance with the design and provisions specified therein.  
• I agree to follow the protocol as written except in cases where necessary to protect the safety, rights, or welfare of a participant, an alteration is required, and the sponsor and IRB 
have been notified prior to the action.  
• I will ensure that the requirements relating to obtaining informed consent and institutional 
review board (IRB) review and approval in 45 CFR 46 are met.  
• I agree to personally conduct or supervise this investigation at this site and to ensure that 
all site staff assisting in the conduct of this study are adequately and appropriately trained 
to implement this version of the protocol and that they are qualified to meet the responsibilities to which they have been assigned.  
• I agree to comply with all the applic able federal, state, and local regulations regarding the 
obligations of clinical investigators as required by [CONTACT_9930] (DHHS), the state, and the IRB.  
SITE’S PRINCIPAL INVESTIGATOR  
          
[INVESTIGATOR_360282]  -[ADDRESS_449157],J.H., Johnson,K., Chalk,M., Schmidt,L., McCarty,D., 2016. 
Extended- Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. J Subst. 
Abuse Treat., 62, [ADDRESS_449158],D.P., LaBelle,C.T., Kretsch,N., 2011. Collaborative care of opi[INVESTIGATOR_2480]- addicted patients in 
primary care using buprenorphine: Five- year experience. Arch Intern Med, 171, [ADDRESS_449159] P & Hoerbst A. (2012). The impact of electronic patient portals 
on patient care: a systematic review of controlled trials. J Med Internet Res, 14(6), e162. doi: 
10.2196/jmir.2238 
Arfken,C.L., Johanson,C.E., di,M.S., Schuster,C.R., 2010. Expanding treatment capacity for 
opi[INVESTIGATOR_360283]- based treatment with buprenorphine: National surveys of 
physicians. J Subst. Abuse Treat., 39, 96 -104. 
ASAM. 'The ASAM National Practice Guideline for the Use of Medications in the Treatment of 
Addiction Involving Opi[INVESTIGATOR_5536].'   2015.  http://www.asam.org/docs/default -source/practice-
support/guidelines -and-consensus -docs/asam -national -practice- guideline-
supplement.pdf?sfvrsn=24 . Accessed February 3, 2017.  
Barry,D., Irwin,K., Jones,E., Becker,W., Tetrault,J., Sullivan,L., Hansen,H., O'Connor,P., Schottenfeld,R., Fiellin,D., 2009. Integrating Buprenorphine Treatment into Office -based 
Practice: a Qualitative Study. J Gen Intern Med, 24, 218 -225. 
Birnbaum,H.G., White,A.G., Schiller,M., Waldman,T., Cleveland,J.M., Roland,C .L., 2011. 
Societal costs of prescription opi[INVESTIGATOR_2554], dependence, and misuse in the [LOCATION_002]. Pain 
Med, 12, 657- 667. 
Centers for Disease Control and Prevention, 2012. CDC grand rounds: Prescription drug 
overdoses -- a U.S. epi[INVESTIGATOR_901]. MMRW, 61, 10 -13. 
Cochran, B. N., A. Flentje, N. C. Heck, J. Van Den Bos, D. Perlman, J. Torres, R. Valuck, and J. Carter. 2014. 'Factors predicting development of opi[INVESTIGATOR_360284]: mathematical modeling usin g a database of commercially -
insured individuals', Drug Alcohol Depend, 138: 202- 8. 
Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opi[INVESTIGATOR_360285]: prospective observational study in [LOCATION_006] General Practice 
Research Database. BMJ. [ADDRESS_449160] 26;341:c5475.  
 Coviello,D.M., Cornish,J.W., Lynch,K.G., Boney,T.Y., Clark,C.A., Lee,J.D., Friedmann,P.D., Nunes,E.V., Kinlock,T.W., Gordon,M.S., Schwartz,R.P., Nuwayser,E.S., O'Brien,C.P., 2012. A multisit e pi[INVESTIGATOR_360286]- release injectable naltrexone treatment for previously opi[INVESTIGATOR_2480]-
dependent parolees and probationers. Subst. Abus., 33, 48- 59. 
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 46  
 Desai JR, Sperl- Hillen JM, & O‘Connor PJ. (2013). Patient preferences in diabetes care: 
overcoming barriers using new strategies. Journal of Comparative Effectiveness Research, 2(4), 
351-354. doi: 10.2217/cer.13.36  
DHHS (Department of Health and Human Services, Assistant Secretary for Planning and 
Evaluation, Office of Disability, Aging and Long- Term Care Poli cy)(2013).  Review of 
medication- assisted treatment guidelines and measures for opi[INVESTIGATOR_360287]. Accessed 
Feb 6, 2017.  https://aspe.hhs.gov/sites/default/files/pdf/205171/MATguidelines.pdf  
Dimitropoulos L. (2014). Health IT Research Priorities To Support the Health Care Delivery 
System of the Future. (Prepared for the Agency for Healthcare Research and Quality under 
Contract No. 290- 2009- [ZIP_CODE]- I.). AHRQ Publication  No. 14 -0072- EF. Rockville, MD,.  
Egan,J., Casadonte,P., Gartenmann,T., Martin,J., McCance- Katz,E., Netherland,J., Renner,J., 
Weiss,L., Saxon,A., Fiellin,D., 2010. The Physician Clinical Support System -Buprenorphine 
(PCSS- B): a Novel Project to Expand/Improve Buprenorphine Treatment. J Gen Intern Med, 25, 
936-941. 
Gilmer TP, P. J. O'Connor, J. M. Sperl -Hillen, W. A. Rush, P. E. Johnson, G. H. Amundson, . . . 
H. L. Ekstrom. (2012). Cost -Effectiveness of an Electronic Medical Record Based Clinical 
Decision Support System. Health Serv Res. doi: 10.1111/j.1475 -6773.2012.[ZIP_CODE]. 
Grant,B.F., Saha,T.D., Ruan,W.J., Goldstein,R.B., Chou,S.P., Jung,J., Zhang,H., Smith,S.M., 
Pi[INVESTIGATOR_11721],R.P., Huang,B., Hasin,D.S., 2016. Epi[INVESTIGATOR_47970] -5 Drug Use Disorder: 
Results From  the National Epi[INVESTIGATOR_7446] -III. JAMA 
Psychiatry, 73, 39 -47. 
Hutchinson,E., Catlin,M., Andrilla,C.H., Baldwin,L.M., Rosenblatt,R.A., 2014. Barriers to primary 
care physicians prescribing buprenorphine. Ann. Fam. Med, 12, 128- 133. 
Kharbanda EO, J. D. Nordin, A. R. Sinaiko, H. L. Ekstrom, J. M. Stultz, N. E. Sherwood, . . . P. 
J. O'Connor. (2015). TeenBP: Development and Pi[INVESTIGATOR_360288] -Linked Clinical Decision 
Support System to Improve Recognition of Hypertension in Adolescents. EGEMS (Wash DC), 
3(2), 1142. doi: 10.[ZIP_CODE]/2327- 9214.1142  
Kunins,H.V., Sohler,N.L., Giovanniello,A., Thompson,D., Cunningham,C.O., 2012. A Buprenorphine Education and Training Program for Primary Care Residents: Implementation and Evaluation. Substance Abuse, 34, 242- 247. 
Liebschutz,J.M., Crooks,D., Herman,D., 2014. Buprenorphine treatment for hospi[INVESTIGATOR_057], opi[INVESTIGATOR_2480]-dependent patients: A randomized clinical trial. JAMA Internal Medicine, 174, 1369 -1376.  
Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, 
Donohue JM. Association between trajectories of buprenorphine treatment and emergency 
department and in- patient utilization. Addiction. 2016 May;111(5):892 -902.  
 
McNeely J, Wu LT, Subramaniam G, Sharma G,  Cathers LA, Svikis D, Sleiter L,  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 47  
 Russell L, Nordeck C, Sharma A, O'Grady KE, Bouk LB, Cushing C, King J, Wahle A, Schwartz 
RP. Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use 
(TAPS) Tool for Substance Use Screening in Primary Care  Patients. Ann Intern Med. 2016 Nov 
15;165(10):690 -699. doi: 10.7326/M16- 0317.  PubMed PMID: 27595276; PubMed Central 
PMCID: PMC5291717.  
 Mohlman MK, Tanzman B, Finison K, Pi[INVESTIGATOR_360289] M, Jones C. Impact of Medication-Assisted 
Treatment for Opi[INVESTIGATOR_360290]. J Subst Abuse Treat. 2016 Aug;67:9 -14. doi: 10.1016/j.jsat.2016.05.002. PubMed 
PMID: 27296656.  
Moore,B.A., Fiellin,D.A., Barry,D.T., Sullivan,L.E., Chawarski,M.C., O'connor ,P.G., 
Schottenfeld,R.S., 2007. Primary care office- based buprenorphine treatment: comparison of 
heroin and prescription opi[INVESTIGATOR_48537]. J Gen Intern Med, 22, 527- 530. 
Netherland,J., Botsko,M., Egan,J.E., Saxon,A.J., Cunningham,C.O., Finkelstein,R., Gourevitch,M.N., Renner,J.A., Sohler,N., Sullivan,L.E., Weiss,L., Fiellin,D.A., 2009. Factors affecting willingness to provide buprenorphine treatment. J Subst. Abuse Treat., 36, 244- 251. 
O'Connor P. (2011). Opportunities to Increase the Effectiveness  of EHR -Based Diabetes 
Clinical Decision Support. Appl Clin Inform, 2(3), 350- 354. doi: 10.4338/ACI -2011- 05-IE-0032  
O'Connor P, J. R. Desai, J. C. Butler, E. O. Kharbanda, & J. M. Sperl -Hillen. (2013). Current 
status and future prospects for electronic poi nt-of-care clinical decision support in diabetes care. 
[Research Support, Non- U.S. Gov't]. Curr Diab Rep, 13(2), 172 -176. doi: 10.1007/s11892 -012-
0350-z 
O'Connor PJ, Sperl -Hillen JM, Rush WA, Johnson PE, Amundson GH, Asche SE, Gilmer TP. 
(2011). Impact of Electronic Health Record Clinical Decision Support on Diabetes Care: A 
Randomized Trial. Ann Fam Med, 9(1), 12- 21. doi: 10.1370/afm.1196  
Roshanov PS, N. Fernandes, J. M. Wilczynski, B. J. Hemens, J. J. You, S. M. Handler, R. B. 
Haynes. (2013). Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials. Research Support, Non- U.S. Gov't]. BMJ, 346, f657. doi: 
10.1136/bmj.f657 
Ross TR, Ng D, Brown JS, Pardee R, Hornbrook MC, Hart G, Steiner JF.  The HMO Research 
Network Virtual Data Warehouose: A Public Data Model to Support Collaboration.  eGEMs 2014.   
Rowe,T.A., Jacapraro,J.S., Rastegar,D.A., 2012. Entry into primary care- based buprenorphine 
treatment is associated with identification and treatment of other chronic medical problems. 
Addict. Sci. Clin. Pract., 7, 22.  
 
 NIDA CTN Protocol  -[ADDRESS_449161] -Effectiveness of Long- Term 
Outpatient Buprenorphine- Naloxone Treatment for Opi[INVESTIGATOR_360291]. J Gen 
Intern Med,  27, 669- 676. 
Soeffing,J.M., Martin,L.D., Fingerhood,M.I., Jasinski,D.R., Rastegar,D.A., 2009. Buprenorphine 
maintenance treatment in a primary care setting: Outcomes at 1 year. Journal of Substance 
Abuse Treatment, 37, 426- 430. 
Sperl -Hillen JM, Averbeck B, Palattao K, Amundson J, Rush B, & O'Connor PJ. (2010). 
Outpatient EHR -Based Diabetes Clinical Decision Support That Works: Lessons Learned From 
Implementing Diabetes Wizard. Diabetes Spectrum, 23(3), 150- 154. 
Substance Abuse and Mental Health Services Administration. Results from the 2007 National 
Survey on Drug Use and Health: National Results. DHHS Publication No. SMA 08- 4343. 2008. 
Rockville, MD, Office of Applied Studies. NSDUH Series H- 34.  
Substance Abuse and Mental Health Services Administration. Treatment epi[INVESTIGATOR_360292] - 
admissions (TEDS -A). http://wwwdasis.samhsa.gov/webt/quicklink/US09.htm. 2012.  
Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. HHS Publication No. (SMA) 14-4863. 2014. Rockville, MD, Office of Applied Studies. NSDUH Series H- 48.  
VA.  Va/Dod Clinical Practice Guideline for the Management of Substance Use Disorders.  2015.  http://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf
 
Accessed February 3, 2017.   
Walley,A., Alperen,J., Cheng,D., Botticelli,M., Castro- Donlan,C., Samet,J., Alford,D., 2008. 
Office -Based Management of Opi[INVESTIGATOR_360293]: Clinical Practices and 
Barriers. J Gen Intern Med, 23, 1393 -1398.  
Weiss,L., Netherland,J., Egan,J.E., Flanigan,T.P., Fiellin,D.A., Finkelstein,R., Altice,F.L., 2011. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the 
BHIVES collaborative. J Acquir. Immune. Defic. Syndr., [ADDRESS_449162] 1, S68- S75. 
WHO (World Health Organization). Opi[INVESTIGATOR_46211]: Preventing and reducing opi[INVESTIGATOR_360294]. UNODC/WHO discussion paper. www.unodc.org/docs/treatment/overdose.pdf
. 2013.   
 
 
 
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 49  
 22.0 APPENDIX A: ADVERSE EVENT REPORTING AND PROCEDURES  
This study is being conducted at the provider level using CDS prompts for evidence- based best 
practice standards related to OUD. As such, we are not trying to change the standard of care for 
OUD in primary care, but rather to help PCPs achieve this standard of care in their care of patients with OUD.  To monitor usability , PCPs will be instructed to use the “Feedback” tab that displays in 
the OUD -CDS to let the study team know of any questions or concerns with the CDS . In particular, 
PCPs are trained to let the research team know via the Feedback tab in the CDS when their clinical judgment led them to a different action than that suggested by [CONTACT_46255] . This automatically 
generates an email that is sent to Drs. Rossom and Sperl -Hillen and the programming team.  The 
research team then discusses this feedback and any necessary actions, and connects with the 
PCP to answer the question, discuss steps taken to address the issue, or gather additional information and further trouble- shoot.  In addition, the emails of Drs. Rossom and Sperl -Hillen are 
listed on the CDS interface for providers, and PCPs are encouraged to contact [CONTACT_360326]’d rather not use the feedback tab in the OUD -CDS.   
  
 NIDA CTN Protocol  -0076 -ot Protocol  Version 1.2 
 COMPUTE  May 8, 2018  
 
 50  
 23.0 APPENDIX B : DATA AND SAFETY MONITORING PLAN  
23.[ADDRESS_449163] an opi[INVESTIGATOR_2427] (OUD) clinical decision support 
(CDS) tool in primary care clinics at HealthPartners and Park Nicollet medical groups.  The CDS 
is based on the NIDA -Blending Initiative white paper, “Clinical Decision Support for Opi[INVESTIGATOR_252245]: Working Group Report,” and will be programmed for use in an electronic medical record (EMR) and tested by [CONTACT_360327] (PCPs) across the healthcare system. Success of these aims will be measured by [CONTACT_360328]. The 
secondary objectives of this pi[INVESTIGATOR_360295]- and post -intervention OUD case- finding, medication- assisted therapy (MAT) and referral 
patterns for PCPs with and without CDS access .  
23.[ADDRESS_449164] (DSMB)  
An independent CTN DSMB will monitor this study.  The DSMB will communicate regarding what type of reports will be needed, as well as frequency.  The CTN DSMB is responsible for conducting periodic reviews of accumulating safety and efficacy data. It will determine whether there is 
support for continuation of the trial, or evidence that study procedures should be changed, or if 
the trial should be halted, for reasons relating to the safety of the study participants, the efficacy of the treatment under study, or inadequate trial performance (e.g., poor recruitment). 
 
Quality Assurance (QA) Monitoring  
It is not anticipated that this study will be assigned a NIDA CCTN CCC monitor.  Quality assurance 
monitoring will be accomplished via pre- implementation testing to confirm that the CDS is 
collecting and storing the data as ex pected.  After implementation and t hroughout the 6- month 
pi[INVESTIGATOR_32731], data will be repeatedly tested to ensure all data elements necessary for analysis are collected on secure servers, and [CONTACT_360336] will conduct periodic test analyses to ensure that all of 
the data she requires for analysis are complete.  Additionally, Drs. Rossom and Sperl -Hillen will 
conduct periodic chart audits to ensure that data collected by [CONTACT_360329].  
  
 NIDA CTN Protocol  -[ADDRESS_449165] makes suggestions for 
patient care that are meant to supplement but not supersede clinical judgment.  PCPs can choose 
to follow or not follow the guidance of the CDS at any given time in any given patient encounter . 
PCPs will be trained to let the research team know via the Feedback tab in the CDS when their 
clinical judgment leads them to a different action than that suggested by [CONTACT_46255]. These events 
will be monitored by [CONTACT_360330].  Every clinical encounter requires medical judgment and poses some element of risk to 
patients.  In the situation of a PCP who is unfamiliar or uncomfortable with OUD, use of the CDS 
will likely make car e safer by [CONTACT_360331], and to encourage referrals when patients are classified as high risk.  We will not be 
encouraging buprenorphine use in non- certified providers, and this will be reinforced thoroughly 
in provider training on the CDS.  For buprenorphine- certified providers, the use of the CDS may 
improve the likelihood of using MAT in high risk situations; however, the risks of MAT are generally 
considered lower than untreated OUD in high- risk situations.   
 NIDA CTN Protocol  -[ADDRESS_449166] folder only accessible by 
[CONTACT_21575].   
23.4.1  Data and Statistics Center Responsibilities 
Not applicable.   
23.5 Data Collection and Entry  
Data from surveys completed by [CONTACT_360332] 6- months and PCP CDS use will be 
collected and stored on a secure server protected by [CONTACT_360333], 
only accessible by [CONTACT_360334].   
23.6 Data Monitoring, Cleaning and Editing  
Data will be monitored, cleaned and edited at HealthPartners Institute on secure servers and 
accessible only by [CONTACT_3462].  
23.7 Data Lock and Transfer  
Not applicable for this single site pi[INVESTIGATOR_799].   